

Endocrine Testing Market Forecasts to 2034 – Global Analysis By Test Type (Human Chorionic Gonadotropin Hormone Test, Prolactin Test, Progesterone Test and Other Test Types), Technology, End User and By Geography

<https://marketpublishers.com/r/E0517B2CF772EN.html>

Date: April 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: E0517B2CF772EN

Abstracts

According to Statistics MRC, the Global Endocrine Testing Market is accounted for \$3.8 billion in 2026 and is expected to reach \$8.3 billion by 2034 growing at a CAGR of 10.4% during the forecast period. Endocrine testing involves the assessment of hormone levels in the body's endocrine system, which regulates various physiological functions. By determining the hormone concentrations in blood, urine, or saliva samples, this diagnostic procedure aids in the identification of hormonal imbalances or disorders. Thyroid hormones, cortisol, insulin, and reproductive hormones like testosterone and estrogen are among the hormones that are frequently tested.

According to the World Health Organization (WHO) in March 2022, 650 million adults, 340 million teenagers, and 39 million children are obese around the world and the number is still rising.

Market Dynamics:

Driver:

Rise in disorders associated with lifestyle

The increase in the endocrine related disorders is partly attributed to alterations in lifestyle patterns, like sedentary lifestyle and unhealthy eating habits. The need for diagnostic tests that can precisely identify hormonal imbalances and offer early

diagnosis of such conditions has increased. Additionally, the market for endocrine testing is expected to grow as medical professionals look for cutting-edge instruments to handle the difficulties in diagnosing lifestyle-related illnesses, stressing the need for accurate and timely hormone evaluations for efficient illness treatment.

Restraint:

Errors in specimen collection

Appropriate specimen collection, storage, and transportation are critical to guaranteeing accurate hormone level measurements. Problems like incorrect sample handling, contamination, or transportation delays can damage the samples' integrity and produce inaccurate test results. Variability in outcomes may also be caused by different healthcare settings using inconsistent methods for data collection. However, it is imperative that these sample-related issues are resolved in order to preserve the accuracy and consistency of endocrine tests, underscoring the necessity of uniform procedures and training for healthcare personnel.

Opportunity:

Companion diagnostics

Companion diagnostics present a unique opportunity in the endocrine testing market by offering tailored solutions for personalized treatment in endocrine disorders. By identifying particular biomarkers or genetic markers, these diagnostics assist medical professionals in matching patients with the most appropriate treatments. This precision approach minimizes side effects, maximizes therapeutic interventions, and improves treatment outcomes in endocrine testing. Moreover, this customized approach enhances patient care while also adding to the general efficacy and affordability of endocrine-related healthcare.

Threat:

Intellectual property challenges

Intellectual property issues are brought about by the creation and application of novel testing techniques, biomarkers, and diagnostic technologies. Businesses that spend money on R&D have to worry about patent infringement because rivals might try to copy or enhance proprietary testing methods. The dynamic nature of endocrine diagnostics

gives rise to inquiries concerning the extent and legitimacy of existing patents, thereby engendering conflicts concerning intellectual property rights.

Covid-19 Impact:

The endocrine testing market has been greatly affected by the COVID-19 pandemic. The endocrine system is one of the organs that the virus can affect, so there is a greater need for endocrine tests to evaluate hormonal imbalances and complications in infected individuals. The endocrine testing industry has seen a surge in innovation and research due to the need for comprehensive diagnostic solutions to comprehend the virus's impact on hormone levels. The focus on diagnosing and treating endocrine disorders has kept the endocrine testing market growing during these difficult times, despite disruptions in the healthcare system.

The immunoassay segment is expected to be the largest during the forecast period

The immunoassay segment has grown substantially because of its high sensitivity and specificity in identifying hormones and associated biomarkers. The need for precise and effective diagnostic techniques has been fueled by the rising incidence of endocrine disorders, including diabetes and thyroid issues. Furthermore, automation, the creation of new assays, and technological developments has all contributed to this segment's growth.

The insulin test segment is expected to have the highest CAGR during the forecast period

Insulin test segment is expected to have the highest CAGR during the forecast period. Insulin tests are in high demand because diabetes management greatly depends on insulin level monitoring. The sector's growth has also been aided by developments in testing technologies, such as faster and more accurate assays. Insulin test adoption has also been influenced by the growing emphasis on personalized medicine and the early detection of diabetes.

Region with largest share:

Asia Pacific region dominated the largest share due to the increasing prevalence of endocrine disorders, rising awareness about hormonal health, and advancements in healthcare infrastructure. The adoption of modern diagnostic technologies and the expansion of healthcare facilities contribute to the market's upward trajectory.

Additionally, heightened investments in research and development, coupled with proactive government initiatives, further fuel the market's expansion.

Region with highest CAGR:

The market has grown profitably in North America due to rising incidence of endocrine disorders and increased public awareness of early disease detection. The region's high healthcare spending and well-established healthcare infrastructure have further stimulated market growth. Furthermore, increased R&D spending in the biotechnology and pharmaceutical industries has sparked innovation in endocrine testing techniques, which has further fuelled the regional growth.

Key players in the market

Some of the key players in Endocrine Testing market include AB Sciex, Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter, Inc., Biomedical Technologies Limited, BioMerieux SA, Bio Rad Laboratories, Inc. , Danaher Corporation, DH Tech. Dev. Pte. Ltd., DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc., Laboratory Corporation of America Holdings, Ortho Clinical Diagnostics, Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG and Thermo Fisher Scientific.

Key Developments:

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc, a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In May 2023, Hologic Inc., a global leader in women's health, announced a partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.

Test Types Covered:

Human Chorionic Gonadotropin Hormone Test

Prolactin Test

Progesterone Test

Insulin Test

Thyroid Stimulating Hormone Test

Luteinizing Hormone Test

Dehydroepiandrosterone Sulfate Test

Estradiol Test

Cortisol Test

Testosterone Test

Follicle Stimulating Hormone Test

Other Test Types

Technologies Covered:

Nucleic Acid Based

Mass Spectroscopy

Chromatography

Immunoassay

Other Technologies

End Users Covered:

Clinical Laboratories

Diagnostic Centers

Hospitals

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030,

2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL ENDOCRINE TESTING MARKET, BY TEST TYPE

- 5.1 Introduction
- 5.2 Human Chorionic Gonadotropin Hormone Test
- 5.3 Prolactin Test
- 5.4 Progesterone Test
- 5.5 Insulin Test
- 5.6 Thyroid Stimulating Hormone Test
- 5.7 Luteinizing Hormone Test
- 5.8 Dehydroepiandrosterone Sulfate Test
- 5.9 Estradiol Test
- 5.10 Cortisol Test
- 5.11 Testosterone Test
- 5.12 Follicle Stimulating Hormone Test
- 5.13 Other Test Types

6 GLOBAL ENDOCRINE TESTING MARKET, BY TECHNOLOGY

- 6.1 Introduction
- 6.2 Nucleic Acid Based
- 6.3 Mass Spectroscopy
- 6.4 Chromatography
- 6.5 Immunoassay
- 6.6 Other Technologies

7 GLOBAL ENDOCRINE TESTING MARKET, BY END USER

- 7.1 Introduction
- 7.2 Clinical Laboratories
- 7.3 Diagnostic Centers
- 7.4 Hospitals
- 7.5 Other End Users

8 GLOBAL ENDOCRINE TESTING MARKET, BY GEOGRAPHY

- 8.1 Introduction
- 8.2 North America
 - 8.2.1 US
 - 8.2.2 Canada

8.2.3 Mexico

8.3 Europe

8.3.1 Germany

8.3.2 UK

8.3.3 Italy

8.3.4 France

8.3.5 Spain

8.3.6 Rest of Europe

8.4 Asia Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 New Zealand

8.4.6 South Korea

8.4.7 Rest of Asia Pacific

8.5 South America

8.5.1 Argentina

8.5.2 Brazil

8.5.3 Chile

8.5.4 Rest of South America

8.6 Middle East & Africa

8.6.1 Saudi Arabia

8.6.2 UAE

8.6.3 Qatar

8.6.4 South Africa

8.6.5 Rest of Middle East & Africa

9 KEY DEVELOPMENTS

9.1 Agreements, Partnerships, Collaborations and Joint Ventures

9.2 Acquisitions & Mergers

9.3 New Product Launch

9.4 Expansions

9.5 Other Key Strategies

10 COMPANY PROFILING

10.1 AB Sciex

- 10.2 Abbott Laboratories
- 10.3 Agilent Technologies Inc.
- 10.4 Beckman Coulter, Inc.
- 10.5 Biomedical Technologies Limited
- 10.6 BioMerieux SA
- 10.7 Bio Rad Laboratories, Inc.
- 10.8 Danaher Corporation
- 10.9 DH Tech. Dev. Pte. Ltd.
- 10.10 DiaSorin SpA
- 10.11 F. Hoffmann-La Roche Ltd
- 10.12 Hologic Inc.
- 10.13 Laboratory Corporation of America Holdings
- 10.14 Ortho Clinical Diagnostics
- 10.15 Qiagen N.V.
- 10.16 Quest Diagnostics
- 10.17 Siemens Healthineers AG
- 10.18 Thermo Fisher Scientific

List Of Tables

LIST OF TABLES

Table 1 Global Endocrine Testing Market Outlook, By Region (2023–2034) (\$MN)

Table 2 Global Endocrine Testing Market Outlook, By Test Type (2023–2034) (\$MN)

Table 3 Global Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023–2034) (\$MN)

Table 4 Global Endocrine Testing Market Outlook, By Prolactin Test (2023–2034) (\$MN)

Table 5 Global Endocrine Testing Market Outlook, By Progesterone Test (2023–2034) (\$MN)

Table 6 Global Endocrine Testing Market Outlook, By Insulin Test (2023–2034) (\$MN)

Table 7 Global Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023–2034) (\$MN)

Table 8 Global Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023–2034) (\$MN)

Table 9 Global Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023–2034) (\$MN)

Table 10 Global Endocrine Testing Market Outlook, By Estradiol Test (2023–2034) (\$MN)

Table 11 Global Endocrine Testing Market Outlook, By Cortisol Test (2023–2034) (\$MN)

Table 12 Global Endocrine Testing Market Outlook, By Testosterone Test (2023–2034) (\$MN)

Table 13 Global Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023–2034) (\$MN)

Table 14 Global Endocrine Testing Market Outlook, By Other Test Types (2023–2034) (\$MN)

Table 15 Global Endocrine Testing Market Outlook, By Technology (2023–2034) (\$MN)

Table 16 Global Endocrine Testing Market Outlook, By Nucleic Acid Based (2023–2034) (\$MN)

Table 17 Global Endocrine Testing Market Outlook, By Mass Spectroscopy (2023–2034) (\$MN)

Table 18 Global Endocrine Testing Market Outlook, By Chromatography (2023–2034) (\$MN)

Table 19 Global Endocrine Testing Market Outlook, By Immunoassay (2023–2034) (\$MN)

Table 20 Global Endocrine Testing Market Outlook, By Other Technologies (2023–2034) (\$MN)

Table 21 Global Endocrine Testing Market Outlook, By End User (2023–2034) (\$MN)

Table 22 Global Endocrine Testing Market Outlook, By Clinical Laboratories (2023–2034) (\$MN)

Table 23 Global Endocrine Testing Market Outlook, By Diagnostic Centers (2023–2034) (\$MN)

Table 24 Global Endocrine Testing Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 25 Global Endocrine Testing Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 26 North America Endocrine Testing Market Outlook, By Country (2023–2034) (\$MN)

Table 27 North America Endocrine Testing Market Outlook, By Test Type (2023–2034) (\$MN)

Table 28 North America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023–2034) (\$MN)

Table 29 North America Endocrine Testing Market Outlook, By Prolactin Test (2023–2034) (\$MN)

Table 30 North America Endocrine Testing Market Outlook, By Progesterone Test (2023–2034) (\$MN)

Table 31 North America Endocrine Testing Market Outlook, By Insulin Test (2023–2034) (\$MN)

Table 32 North America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023–2034) (\$MN)

Table 33 North America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023–2034) (\$MN)

Table 34 North America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023–2034) (\$MN)

Table 35 North America Endocrine Testing Market Outlook, By Estradiol Test (2023–2034) (\$MN)

Table 36 North America Endocrine Testing Market Outlook, By Cortisol Test (2023–2034) (\$MN)

Table 37 North America Endocrine Testing Market Outlook, By Testosterone Test (2023–2034) (\$MN)

Table 38 North America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023–2034) (\$MN)

Table 39 North America Endocrine Testing Market Outlook, By Other Test Types (2023–2034) (\$MN)

Table 40 North America Endocrine Testing Market Outlook, By Technology (2023–2034) (\$MN)

Table 41 North America Endocrine Testing Market Outlook, By Nucleic Acid Based

(2023–2034) (\$MN)

Table 42 North America Endocrine Testing Market Outlook, By Mass Spectroscopy

(2023–2034) (\$MN)

Table 43 North America Endocrine Testing Market Outlook, By Chromatography

(2023–2034) (\$MN)

Table 44 North America Endocrine Testing Market Outlook, By Immunoassay

(2023–2034) (\$MN)

Table 45 North America Endocrine Testing Market Outlook, By Other Technologies

(2023–2034) (\$MN)

Table 46 North America Endocrine Testing Market Outlook, By End User (2023–2034)

(\$MN)

Table 47 North America Endocrine Testing Market Outlook, By Clinical Laboratories

(2023–2034) (\$MN)

Table 48 North America Endocrine Testing Market Outlook, By Diagnostic Centers

(2023–2034) (\$MN)

Table 49 North America Endocrine Testing Market Outlook, By Hospitals (2023–2034)

(\$MN)

Table 50 North America Endocrine Testing Market Outlook, By Other End Users

(2023–2034) (\$MN)

Table 51 Europe Endocrine Testing Market Outlook, By Country (2023–2034) (\$MN)

Table 52 Europe Endocrine Testing Market Outlook, By Test Type (2023–2034) (\$MN)

Table 53 Europe Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin

Hormone Test (2023–2034) (\$MN)

Table 54 Europe Endocrine Testing Market Outlook, By Prolactin Test (2023–2034)

(\$MN)

Table 55 Europe Endocrine Testing Market Outlook, By Progesterone Test (2023–2034)

(\$MN)

Table 56 Europe Endocrine Testing Market Outlook, By Insulin Test (2023–2034) (\$MN)

Table 57 Europe Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone

Test (2023–2034) (\$MN)

Table 58 Europe Endocrine Testing Market Outlook, By Luteinizing Hormone Test

(2023–2034) (\$MN)

Table 59 Europe Endocrine Testing Market Outlook, By Dehydroepiandrosterone

Sulfate Test (2023–2034) (\$MN)

Table 60 Europe Endocrine Testing Market Outlook, By Estradiol Test (2023–2034)

(\$MN)

Table 61 Europe Endocrine Testing Market Outlook, By Cortisol Test (2023–2034)

(\$MN)

Table 62 Europe Endocrine Testing Market Outlook, By Testosterone Test (2023–2034)

(\$MN)

Table 63 Europe Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023–2034) (\$MN)

Table 64 Europe Endocrine Testing Market Outlook, By Other Test Types (2023–2034) (\$MN)

Table 65 Europe Endocrine Testing Market Outlook, By Technology (2023–2034) (\$MN)

Table 66 Europe Endocrine Testing Market Outlook, By Nucleic Acid Based (2023–2034) (\$MN)

Table 67 Europe Endocrine Testing Market Outlook, By Mass Spectroscopy (2023–2034) (\$MN)

Table 68 Europe Endocrine Testing Market Outlook, By Chromatography (2023–2034) (\$MN)

Table 69 Europe Endocrine Testing Market Outlook, By Immunoassay (2023–2034) (\$MN)

Table 70 Europe Endocrine Testing Market Outlook, By Other Technologies (2023–2034) (\$MN)

Table 71 Europe Endocrine Testing Market Outlook, By End User (2023–2034) (\$MN)

Table 72 Europe Endocrine Testing Market Outlook, By Clinical Laboratories (2023–2034) (\$MN)

Table 73 Europe Endocrine Testing Market Outlook, By Diagnostic Centers (2023–2034) (\$MN)

Table 74 Europe Endocrine Testing Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 75 Europe Endocrine Testing Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 76 Asia Pacific Endocrine Testing Market Outlook, By Country (2023–2034) (\$MN)

Table 77 Asia Pacific Endocrine Testing Market Outlook, By Test Type (2023–2034) (\$MN)

Table 78 Asia Pacific Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023–2034) (\$MN)

Table 79 Asia Pacific Endocrine Testing Market Outlook, By Prolactin Test (2023–2034) (\$MN)

Table 80 Asia Pacific Endocrine Testing Market Outlook, By Progesterone Test (2023–2034) (\$MN)

Table 81 Asia Pacific Endocrine Testing Market Outlook, By Insulin Test (2023–2034) (\$MN)

Table 82 Asia Pacific Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023–2034) (\$MN)

Table 83 Asia Pacific Endocrine Testing Market Outlook, By Luteinizing Hormone Test

(2023–2034) (\$MN)

Table 84 Asia Pacific Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023–2034) (\$MN)

Table 85 Asia Pacific Endocrine Testing Market Outlook, By Estradiol Test (2023–2034) (\$MN)

Table 86 Asia Pacific Endocrine Testing Market Outlook, By Cortisol Test (2023–2034) (\$MN)

Table 87 Asia Pacific Endocrine Testing Market Outlook, By Testosterone Test (2023–2034) (\$MN)

Table 88 Asia Pacific Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023–2034) (\$MN)

Table 89 Asia Pacific Endocrine Testing Market Outlook, By Other Test Types (2023–2034) (\$MN)

Table 90 Asia Pacific Endocrine Testing Market Outlook, By Technology (2023–2034) (\$MN)

Table 91 Asia Pacific Endocrine Testing Market Outlook, By Nucleic Acid Based (2023–2034) (\$MN)

Table 92 Asia Pacific Endocrine Testing Market Outlook, By Mass Spectroscopy (2023–2034) (\$MN)

Table 93 Asia Pacific Endocrine Testing Market Outlook, By Chromatography (2023–2034) (\$MN)

Table 94 Asia Pacific Endocrine Testing Market Outlook, By Immunoassay (2023–2034) (\$MN)

Table 95 Asia Pacific Endocrine Testing Market Outlook, By Other Technologies (2023–2034) (\$MN)

Table 96 Asia Pacific Endocrine Testing Market Outlook, By End User (2023–2034) (\$MN)

Table 97 Asia Pacific Endocrine Testing Market Outlook, By Clinical Laboratories (2023–2034) (\$MN)

Table 98 Asia Pacific Endocrine Testing Market Outlook, By Diagnostic Centers (2023–2034) (\$MN)

Table 99 Asia Pacific Endocrine Testing Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 100 Asia Pacific Endocrine Testing Market Outlook, By Other End Users (2023–2034) (\$MN)

Table 101 South America Endocrine Testing Market Outlook, By Country (2023–2034) (\$MN)

Table 102 South America Endocrine Testing Market Outlook, By Test Type (2023–2034) (\$MN)

Table 103 South America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023–2034) (\$MN)

Table 104 South America Endocrine Testing Market Outlook, By Prolactin Test (2023–2034) (\$MN)

Table 105 South America Endocrine Testing Market Outlook, By Progesterone Test (2023–2034) (\$MN)

Table 106 South America Endocrine Testing Market Outlook, By Insulin Test (2023–2034) (\$MN)

Table 107 South America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023–2034) (\$MN)

Table 108 South America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023–2034) (\$MN)

Table 109 South America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023–2034) (\$MN)

Table 110 South America Endocrine Testing Market Outlook, By Estradiol Test (2023–2034) (\$MN)

Table 111 South America Endocrine Testing Market Outlook, By Cortisol Test (2023–2034) (\$MN)

Table 112 South America Endocrine Testing Market Outlook, By Testosterone Test (2023–2034) (\$MN)

Table 113 South America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023–2034) (\$MN)

Table 114 South America Endocrine Testing Market Outlook, By Other Test Types (2023–2034) (\$MN)

Table 115 South America Endocrine Testing Market Outlook, By Technology (2023–2034) (\$MN)

Table 116 South America Endocrine Testing Market Outlook, By Nucleic Acid Based (2023–2034) (\$MN)

Table 117 South America Endocrine Testing Market Outlook, By Mass Spectroscopy (2023–2034) (\$MN)

Table 118 South America Endocrine Testing Market Outlook, By Chromatography (2023–2034) (\$MN)

Table 119 South America Endocrine Testing Market Outlook, By Immunoassay (2023–2034) (\$MN)

Table 120 South America Endocrine Testing Market Outlook, By Other Technologies (2023–2034) (\$MN)

Table 121 South America Endocrine Testing Market Outlook, By End User (2023–2034) (\$MN)

Table 122 South America Endocrine Testing Market Outlook, By Clinical Laboratories

(2023–2034) (\$MN)

Table 123 South America Endocrine Testing Market Outlook, By Diagnostic Centers

(2023–2034) (\$MN)

Table 124 South America Endocrine Testing Market Outlook, By Hospitals (2023–2034)

(\$MN)

Table 125 South America Endocrine Testing Market Outlook, By Other End Users

(2023–2034) (\$MN)

Table 126 Middle East & Africa Endocrine Testing Market Outlook, By Country

(2023–2034) (\$MN)

Table 127 Middle East & Africa Endocrine Testing Market Outlook, By Test Type

(2023–2034) (\$MN)

Table 128 Middle East & Africa Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023–2034) (\$MN)

Table 129 Middle East & Africa Endocrine Testing Market Outlook, By Prolactin Test

(2023–2034) (\$MN)

Table 130 Middle East & Africa Endocrine Testing Market Outlook, By Progesterone

Test (2023–2034) (\$MN)

Table 131 Middle East & Africa Endocrine Testing Market Outlook, By Insulin Test

(2023–2034) (\$MN)

Table 132 Middle East & Africa Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023–2034) (\$MN)

Table 133 Middle East & Africa Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023–2034) (\$MN)

Table 134 Middle East & Africa Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023–2034) (\$MN)

Table 135 Middle East & Africa Endocrine Testing Market Outlook, By Estradiol Test (2023–2034) (\$MN)

Table 136 Middle East & Africa Endocrine Testing Market Outlook, By Cortisol Test (2023–2034) (\$MN)

Table 137 Middle East & Africa Endocrine Testing Market Outlook, By Testosterone Test (2023–2034) (\$MN)

Table 138 Middle East & Africa Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023–2034) (\$MN)

Table 139 Middle East & Africa Endocrine Testing Market Outlook, By Other Test Types (2023–2034) (\$MN)

Table 140 Middle East & Africa Endocrine Testing Market Outlook, By Technology (2023–2034) (\$MN)

Table 141 Middle East & Africa Endocrine Testing Market Outlook, By Nucleic Acid Based (2023–2034) (\$MN)

Table 142 Middle East & Africa Endocrine Testing Market Outlook, By Mass Spectroscopy (2023–2034) (\$MN)

Table 143 Middle East & Africa Endocrine Testing Market Outlook, By Chromatography (2023–2034) (\$MN)

Table 144 Middle East & Africa Endocrine Testing Market Outlook, By Immunoassay (2023–2034) (\$MN)

Table 145 Middle East & Africa Endocrine Testing Market Outlook, By Other Technologies (2023–2034) (\$MN)

Table 146 Middle East & Africa Endocrine Testing Market Outlook, By End User (2023–2034) (\$MN)

Table 147 Middle East & Africa Endocrine Testing Market Outlook, By Clinical Laboratories (2023–2034) (\$MN)

Table 148 Middle East & Africa Endocrine Testing Market Outlook, By Diagnostic Centers (2023–2034) (\$MN)

Table 149 Middle East & Africa Endocrine Testing Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 150 Middle East & Africa Endocrine Testing Market Outlook, By Other End Users (2023–2034) (\$MN)

I would like to order

Product name: Endocrine Testing Market Forecasts to 2034 – Global Analysis By Test Type (Human Chorionic Gonadotropin Hormone Test, Prolactin Test, Progesterone Test and Other Test Types), Technology, End User and By Geography

Product link: <https://marketpublishers.com/r/E0517B2CF772EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E0517B2CF772EN.html>